Risk-Sharing Drug Rebate Contracts: Do They Live Up To The Hype?
Manufacturers and payers will continue to work on innovative pricing arrangements, roundtable panelists said, but they are likely to be less complex and resource intensive than many of the risk-sharing contracts announced to date, particularly in Europe.
You may also be interested in...
The former CMS and FDA head suggested at an AHIP conference that performance-based payments could help pave the way for a new “pricing model” for specialty drugs in the U.S.
In recent years, it has become standard practice for marketers of pharmaceutical and biotechnology products to offer a whole host of wraparound services to bolster the value proposition of their brands. Why not sell them?
The increasing pressure on payers and providers to curtail rising health care costs should lead drug companies to adjust marketing practices to the new realities, Merck’s Jay Galeota suggested. He pointed to risk-sharing as an area where interests can be aligned.